Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis

Diabetes Research and Clinical Practice

Volumn 109, Issue 3, 2015, Pages 451-460

  Zhong, Xihua ^a   Zhang, Tianyi ^a   Liu, Yuzhou ^b   Wei, Xin ^b   Zhang, Xinji ^a   Qin, Yingyi ^a   Jin, Zhichao ^a   Chen, Qi ^a   Ma, Xiuqiang ^a   Wang, Rui ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Glucagons like peptide 1 receptor agonist; Injectable antidiabetic agent; Metformin; Network meta analysis; Sulfonylurea; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; RECOMBINANT HUMAN INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT CHANGE; WEIGHT REDUCTION; AGONISTS; BLOOD; COMMUNITY CARE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INJECTION; MALE; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE;

ADULT; BLOOD GLUCOSE; COMMUNITY NETWORKS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; MALE; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE;

EID: 84940793372     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.05.048     Document Type: Review

References (42)

1. International Diabetes Federation Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014, 104(1):1-52.
2. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009, 32:193-203.
3. National Collaborating Centre for Chronic Conditions Type 2 diabetes: national clinical guideline for management in primary and secondary care (update) 2008, Royal College of Physicians, London.
4. Liu S.C., Tu Y.K., Chien M.N., Chien K.L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in participants with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012, 14(9):810-820.
5. Scott D.A., Boye K.S., Timlin L., Clark J.F., Best J.H. A network meta-analysis to compare glycaemic control in participants with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 2013, 15(3):213-223.
6. Gross J.L., Kramer C.K., Leitão C.B., Hawkins N., Viana L.V., Schaan B.D., et al. Diabetes and endocrinology meta-analysis group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011, 154(May (10)):672-679.
7. Abdul-Ghani M.A., Williams K., Kanat M., Altuntas Y., DeFronzo R.A. Insulin vs GLP-1 analogues in poorly controlled type 2 diabetic subjects on oral therapy: a meta-analysis. J Endocrinol Invest 2013, 36(3):168-173.
8. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
9. Diamant M., Van Gaal L., Stranks S., et al. Once weekly exenatide compared with insulin glargine titrated to target in participants with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234-2243.
10. Davies M., Heller S., Sreenan S., Sapin H., Adetunji O., Tahbaz A., et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in participants with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care 2013, 36(5):1368-1376.
11. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097. The PRISMA group.
12. Krahn U., Binder H., König J. A graphical tool for locating inconsistency in network meta analyses. BMC Med Res Method 2013, 13:35.
13. Higgins J.P.T., Jackson D., Barrett J.K., Lu G., Ades A.E., White I.R. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012, 3(2):98-110.
14. netmeta. Network meta-analysis with R (2014). R Package Version 0. 6-0. netmeta, 〈http://CRAN.R-project.org/package=netmeta〉.
15. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
16. Viechtbauer Wolfgang Conducting meta-analyses in R with the metafor package. J Stat Softw 2010, 36(3):1-48. 〈http://www.jstatsoft.org/v36/i03/〉.
17. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated participants with type 2 diabetes. Diabetes Care 2004, 27(11):2628-2635.
18. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated participants with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
19. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G., et al. Exenatide versus insulin glargine in participants with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
20. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005, 28(2):254-259.
21. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in participants with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
22. Holman R.R., Thorne K.I., Farmer A.J., Davies M.J., Keenan J.F., Paul S., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357(Oct (17)):1716-1730.
23. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in participants with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
24. Bergenstal R., Lewin A., Bailey T., Chang D., Gylvin T., Roberts V., et al. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009, 25:65-75.
25. Bunck M.C., Diamant M., Corner A., et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic participants. Diabetes Care 2009, 32:762-768.
26. Gao Y., Yoon K.H., Chuang L.M., Mohan V., Ning G., Shah S., et al. Efficacy and safety of exenatide in participants of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009, 83(1):69-76.
27. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., et al. Liraglutide effect and action in diabetes 5 (LEAD-5) met_SU study group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met_SU): a randomized controlled trial. Diabetologia 2009, 52:2046-2055.
28. Apovian C.M., Bergenstal R.M., Cuddihy R.M., Qu Y., Lenox S., Lewis M.S., et al. Effects of exenatide combined with lifestyle modification in participants with type 2 diabetes. Am J Med 2010, 123(5):468.e9-468.e17.
29. Kaku K., Rasmussen M.F., Clauson P., Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese participants with type 2 diabetes. Diabetes Obes Metab 2010, 12(4):341-347.
30. Gallwitz B., Böhmer M., Segiet T., Mölle A., Milek K., Becker B., et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated participants with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011, 34(3):604-606.
31. Derosa Giuseppe, Cicero Arrigo F.G., Franzetti Ivano G., Querci Fabrizio, Carbone Anna, Ciccarelli Leonardina, et al. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. Can J Physiol Pharmacol 2013, 91:724-732.
32. Hoerger T.J., Segel J.E., Gregg E.W., Saaddine J.B. Is glycemic control improving in U.S. adults?. Diabetes Care 2008, 31:81-86.
33. Grant R.W., Buse J.B., Meigs F Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005, 28:337-442. University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team.
34. Diamant M., Van Gaal L., Guerci B., Stranks S., Han J., Malloy J., et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014, 2(6):464-473. pii: S2213-8587(14)70029-4.
35. Yamamoto-Honda R1, Ehara H., Kitazato H., Takahashi Y., Kawazu S., Akanuma Y., et al. The long-term coronary heart disease risk of previously obese participants with type 2 diabetes mellitus. BMC Endocr Disord 2013 Oct 3, 13(1):38.
36. Ottney A. Glucagon-like peptide-1 receptor agonists for weight loss in adult participants without diabetes. Am J Health Syst Pharm 2013, 70(Dec (23)):2097-2103.
37. Sun F., Yu K., Yang Z., Wu S., Zhang Y., Shi L., et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res 2012, 2012:230624.
38. Valerón P.F., de Pablos-Velasco P.L. Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus. Med Clin (Barc) 2013, 141(Suppl 2):20-25.
39. Sanyal D., Majumdar A. Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting. Indian J Endocrinol Metab 2013 Oct, 17(Oct (Suppl 1)):S301-S303.
40. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. LEAD-3 (Mono) study group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373(Feb (9662)):473-481.
41. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32(1):84-90.
42. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R.A., Hu P., et al. INITIATE study group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28(2):260-265.